Flexus Biosciences Acquired For $1.25 Billion
San Carlos-based Flexus Biosciences, which is developing cancer therapeutics, has been acquired by Bristol-Myers Squibb. The deal is worth $1.25 billion, split between $800M upfront and earnout worth up to $450M. Flexus Biosciences was venture backed by Kleiner Perkins Caufield and Byers, The Column Group, Celgene, and Amgen.
posted on Tuesday, February 24, 2015
Related companies:
Flexus Biosciences, Inc.
Related stories:
> Entelos Acquires Iconix Biosciences
> Cell Biosciences Buys Alpha Innotech, Raises $19M
> 3-V Biosciences Finds $20M In Funding
> Pacific Biosciences Raises $50M
> Imago Biosciences Sees $26.5M
silicontap.com Home